P-198 - Clinical outcomes of everolimus in patients with advanced pancreatic neuroendocrine tumor: A multicenter study in Korea

Abstract

Introduction: Everolimus is a standard treatment option for advanced pancreatic neuroendocrine tumor. This multicenter study evaluated the efficacy and safety of everolimus in low grade- and intermediate grade advanced pancreatic neuroendocrine tumors (pNETs). Methods: Tumors were graded according to the World Health Organization 2010 classification system. Patients who received everolimus as first line or second line chemotherapy with low grade- and intermediate grade pNETs were included between 2002 and 2014. Results: A total of 40 patients with pNETs were included in this study. The median age was 54.5 years (range; 19-83 years). Twelve patients (30%) underwent recurrence. There were 11 patients (27.5%) with low grade pNETs and 29 (72.5%) with intermediate. Everolimus was administered in 30 patients (75%) as first-line and 10 patients (25%) as second. The median progression free survival (PFS) with low and intermediate grade pNETs was significantly different (median not reached vs. 11 months, P = 0.015). In multivariate analysis, tumor grade (intermediate grade; Hazard ratio = 5.46, 95% CI 1.32-22.51, P = 0.026) was the only independent prognostic factor for PFS in pNETs. The most common adverse events were stomatitis, skin rash and anemia. Conclusion: In the everolimus treatment for pNETs, WHO 2010 grade acts as an important determinant for PFS. However, the incidence of adverse events was acceptable.